Articles avec mandats d'accès public - Michael J. EckEn savoir plus
Non disponibles : 4
Leveraging gas-phase fragmentation pathways for improved identification and selective detection of targets modified by covalent probes
SB Ficarro, CM Browne, JD Card, WM Alexander, T Zhang, E Park, ...
Analytical chemistry 88 (24), 12248-12254, 2016
Exigences : US National Institutes of Health
Discovery and structural characterization of ATP-site ligands for the wild-type and V617F mutant JAK2 pseudokinase domain
R McNally, Q Li, K Li, C Dekker, E Vangrevelinghe, M Jones, P Chène, ...
ACS Chemical Biology 14 (4), 587-593, 2019
Exigences : US Department of Energy, US National Institutes of Health
ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases
Z Li, W Lu, TS Beyett, SB Ficarro, J Jiang, J Tse, AYJ Kim, JA Marto, J Che, ...
Journal of Medicinal Chemistry 67 (4), 2837-2848, 2024
Exigences : US National Institutes of Health
Development of Mutant-Selective Allosteric EGFR Inhibitors for Drug-Resistant Lung Cancer
T Beyett, C To, DE Heppner, TW Gero, NS Gray, DA Scott, PA Jänne, ...
The Journal of Pharmacology and Experimental Therapeutics 385, 517, 2023
Exigences : US National Institutes of Health
Disponibles quelque part : 85
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
W Zhou, D Ercan, L Chen, CH Yun, D Li, M Capelletti, AB Cortot, ...
Nature 462 (7276), 1070-1074, 2009
Exigences : US National Institutes of Health
Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors
Y Jia, CH Yun, E Park, D Ercan, M Manuia, J Juarez, C Xu, K Rhee, ...
Nature 534 (7605), 129-132, 2016
Exigences : US National Institutes of Health
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
H Yasuda, E Park, CH Yun, NJ Sng, AR Lucena-Araujo, WL Yeo, ...
Science translational medicine 5 (216), 216ra177-216ra177, 2013
Exigences : US National Institutes of Health
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, ...
Cancer discovery 1 (1), 78-89, 2011
Exigences : US National Institutes of Health, German Research Foundation
The FERM domain: organizing the structure and function of FAK
MC Frame, H Patel, B Serrels, D Lietha, MJ Eck
Nature reviews Molecular cell biology 11 (11), 802-814, 2010
Exigences : US National Institutes of Health, Cancer Research UK
EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors
D Ercan, HG Choi, CH Yun, M Capelletti, T Xie, MJ Eck, NS Gray, ...
Clinical cancer research 21 (17), 3913-3923, 2015
Exigences : US National Institutes of Health
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
T Sasaki, K Okuda, W Zheng, J Butrynski, M Capelletti, L Wang, NS Gray, ...
Cancer research 70 (24), 10038-10043, 2010
Exigences : US National Institutes of Health
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
H Greulich, B Kaplan, P Mertins, TH Chen, KE Tanaka, CH Yun, X Zhang, ...
Proceedings of the National Academy of Sciences 109 (36), 14476-14481, 2012
Exigences : US National Institutes of Health
Cyclic di-GMP sensing via the innate immune signaling protein STING
Q Yin, Y Tian, V Kabaleeswaran, X Jiang, D Tu, MJ Eck, ZJ Chen, H Wu
Molecular cell 46 (6), 735-745, 2012
Exigences : US National Institutes of Health
Single and dual targeting of mutant EGFR with an allosteric inhibitor
C To, J Jang, T Chen, E Park, M Mushajiang, DJH De Clercq, M Xu, ...
Cancer discovery 9 (7), 926-943, 2019
Exigences : US Department of Energy, US National Institutes of Health
Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
E Park, S Rawson, K Li, BW Kim, SB Ficarro, GGD Pino, H Sharif, ...
Nature 575 (7783), 545-550, 2019
Exigences : US Department of Energy, US National Institutes of Health
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
MJ Eck, CH Yun
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1804 (3), 559-566, 2010
Exigences : US National Institutes of Health
Structure and ubiquitination-dependent activation of TANK-binding kinase 1
D Tu, Z Zhu, AY Zhou, C Yun, KE Lee, AV Toms, Y Li, GP Dunn, E Chan, ...
Cell reports 3 (3), 747-758, 2013
Exigences : US National Institutes of Health
Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Z Zhu, AR Aref, TJ Cohoon, TU Barbie, Y Imamura, S Yang, SE Moody, ...
Cancer discovery 4 (4), 452-465, 2014
Exigences : US National Institutes of Health
Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent
J Ni, Q Liu, S Xie, C Carlson, T Von, K Vogel, S Riddle, C Benes, M Eck, ...
Cancer discovery 2 (5), 425-433, 2012
Exigences : US National Institutes of Health
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
M Red Brewer, CH Yun, D Lai, MA Lemmon, MJ Eck, W Pao
Proceedings of the National Academy of Sciences 110 (38), E3595-E3604, 2013
Exigences : US National Institutes of Health
Les informations concernant la publication et le financement sont déterminées automatiquement par un programme informatique